Cargando…

A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia

B-cell acute lymphoblastic leukemia (B-ALL) is a malignant tumor originating from B-lineage lymphoid precursor cells. The incidence of B-ALL is about 80% in childhood acute leukemia and 20% in adults. In recent years, with standardized treatment guided by risk stratification, the long-term disease-f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hao, Meng, Guoyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742090/
https://www.ncbi.nlm.nih.gov/pubmed/36518591
http://dx.doi.org/10.1097/BS9.0000000000000126
_version_ 1784848458547462144
author Zhang, Hao
Meng, Guoyu
author_facet Zhang, Hao
Meng, Guoyu
author_sort Zhang, Hao
collection PubMed
description B-cell acute lymphoblastic leukemia (B-ALL) is a malignant tumor originating from B-lineage lymphoid precursor cells. The incidence of B-ALL is about 80% in childhood acute leukemia and 20% in adults. In recent years, with standardized treatment guided by risk stratification, the long-term disease-free survival rate of children is about 80%, while that of adults is less than 40%. However, the specific pathogenesis of the newly identified B-ALL and the targeted therapy strategies have not been vigorously investigated. In this review, we highlight the recent breakthroughs in mechanistic studies and novel therapeutic options in DUX4- and MEF2D-subtype B-ALLs.
format Online
Article
Text
id pubmed-9742090
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97420902022-12-13 A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia Zhang, Hao Meng, Guoyu Blood Sci Review Article B-cell acute lymphoblastic leukemia (B-ALL) is a malignant tumor originating from B-lineage lymphoid precursor cells. The incidence of B-ALL is about 80% in childhood acute leukemia and 20% in adults. In recent years, with standardized treatment guided by risk stratification, the long-term disease-free survival rate of children is about 80%, while that of adults is less than 40%. However, the specific pathogenesis of the newly identified B-ALL and the targeted therapy strategies have not been vigorously investigated. In this review, we highlight the recent breakthroughs in mechanistic studies and novel therapeutic options in DUX4- and MEF2D-subtype B-ALLs. Lippincott Williams & Wilkins 2022-07-20 /pmc/articles/PMC9742090/ /pubmed/36518591 http://dx.doi.org/10.1097/BS9.0000000000000126 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Medical Association (CMA) and Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College (IHCAMS). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Review Article
Zhang, Hao
Meng, Guoyu
A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia
title A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia
title_full A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia
title_fullStr A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia
title_full_unstemmed A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia
title_short A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia
title_sort typical bedside-to-bench investigation of leukemogenic driver mef2d fusion reveals new targeted therapy in b-cell acute lymphoblastic leukemia
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742090/
https://www.ncbi.nlm.nih.gov/pubmed/36518591
http://dx.doi.org/10.1097/BS9.0000000000000126
work_keys_str_mv AT zhanghao atypicalbedsidetobenchinvestigationofleukemogenicdrivermef2dfusionrevealsnewtargetedtherapyinbcellacutelymphoblasticleukemia
AT mengguoyu atypicalbedsidetobenchinvestigationofleukemogenicdrivermef2dfusionrevealsnewtargetedtherapyinbcellacutelymphoblasticleukemia
AT zhanghao typicalbedsidetobenchinvestigationofleukemogenicdrivermef2dfusionrevealsnewtargetedtherapyinbcellacutelymphoblasticleukemia
AT mengguoyu typicalbedsidetobenchinvestigationofleukemogenicdrivermef2dfusionrevealsnewtargetedtherapyinbcellacutelymphoblasticleukemia